Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 IRIDEX Corporation (NASDAQ: IRIX ... quarter 2015 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, August 6, 2015 ... business developments. Interested parties may access the ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of #MedicareMonday ... remind you about some of our Medicare resources and continue highlighting the success of ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... ResMed Inc. (NYSE: RMD ) announced today that it will be ... ... 4, 2010 ; Jefferies Global Life Sciences Conference at the Grand Hyatt in ... Conference at the Four Seasons in Chicago on June 16, 2010 ; ...
... April 27 AstraZeneca LP and AstraZeneca ... resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug ... by the Food and Drug Administration (FDA), the Departments ... Fraud Enforcement Action Team (HEAT) announced today.  Such unapproved ...
Cached Medicine Technology:ResMed Inc. to Present at Upcoming Conferences 2Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 2Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 3Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 4Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 5Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 6
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... ... is a reputable source of authentic USA vs. Australia tickets at Ford Field ... Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup ... was awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... ... July 31, 2015 , ... A family-run business in ... from ingredients sourced all over the world, then manufactured into specific formulations in ... developed the highest-quality oils in the industry, which we are bringing to consumers ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... PHILADELPHIA Scientists and clinicians from around the ... at the American Association for Cancer Researchs second ... Development. The conference is subtitled Maximizing Opportunities for ... diagnostics to provide new strategies for tailoring therapies ...
... LOMA LINDA, Calif., Sept. 10 Loma ... Day Adventist institution located,in Southern California, has ... physician referrals and outbound reminder calls for ... seeking physician referrals for breast care, psychology, ...
... Harvard Medical School,researchers have honored BlueCross BlueShield of ... providers to obtain member pre-,certifications in seconds over ... less costly. Researchers from the medical school,s ... tool as one of seven national,BlueWorks(R) winners in ...
... ABBOTT PARK, Ill., Sept. 10 Abbott (NYSE:,ABT) ... named to the Dow Jones,Sustainability World Index and ... third consecutive year. This selection recognizes Abbott,s,continued leadership ... is a critical part of our approach to ...
... ATLANTA, Sept. 10 Coalition America, Inc. (CAI),announces ... strategy officer who,will lead the deployment efforts of ... continuous new product development,initiatives. Brown comes to ... the,healthcare industry having held management roles in various ...
Cached Medicine News:Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Scientists, physicians present latest findings in 'personalized' cancer treatment and prevention 2Health News:Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Women's Services Programs and Departments 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2Health News:Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer 2
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
... Pipettor is the #1 Pipettor for ... comfort, and reliability. Continuously adjustable. Features ... sub-micrometer. Easy interchangeable ejector buttons to ... Adjustable rapid pipet tip ejector with ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
Medicine Products: